SynCav 1
Alternative Names: SynCav-1Latest Information Update: 28 Oct 2024
At a glance
- Originator University of California, San Diego
- Developer CavoGene LifeSciences
- Class Antidementias; Antiparkinsonians; Gene therapies
- Mechanism of Action Caveolin 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Brain injuries; Cognition disorders; Multiple sclerosis; Parkinson's disease; Spinal cord injuries
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Multiple-sclerosis in USA (Parenteral)
- 28 Oct 2024 No recent reports of development identified for research development in Parkinson's-disease in USA (Parenteral)
- 28 May 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)